NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Neutrolis Inc

Neutrolis Inc

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://neutrolis.com/

Last Round

Series B

Oct 29, 2025

Total Funding Raised

$33.56M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Neutrolis Inc is a biotechnology company that develops precision therapies for autoimmune and inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyneutrophil extracellular trapsNETsenzyme therapeuticsautoimmune diseaseprecision medicinedrug discoverybiologicssystemic lupus erythematosusSLErheumatoid arthritisRAbiomarker technologynon-immunosuppressive therapyclinical-stage biotechdrug licensingprotein engineering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neutrolis Inc Comparables

Compare Neutrolis Inc with similar companies based on industry and business-model similarity.

Neutrolis Inc comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ardiyon Bio
85%
Citryll
81%
Sonoma Biotherapeutics
64%

Neutrolis Inc Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BOct 29, 2025
VC RoundJul 8, 2025
VC RoundFeb 28, 2025
Series ADec 3, 2021
GrantAug 3, 2020
Accelerator
Nov 28, 2017

Key People

Founding team and executive leadership

Abdul R

Co-Founder, Co-President COO

Founding Team

Toby Fox

Co-founder, Chief Executive Officer

Founding Team

Sean McElduff

CFO

Executive Team

Neutrolis Inc Investors

Notable investors and investment history

Neutrolis Inc investors
InvestorRounds
U.S. Department of Health and Human ServicesGrant
NIH RADxGrant
Prefix CapitalVC Round, Series A, Seed
PBJ CapitalVC Round, Series A
PfizerAccelerator
Morningside GroupSeries A
National Institutes of Health (NIH)Grant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 16, 2026

    Monthly visitors increased 46% MoM.

  • Apr 15, 2026

    Caren Deardorf appointed as Chief Business & Strategy Officer.

Neutrolis Inc Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Neutrolis Inc Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Neutrolis Inc's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range15
Year Founded2017
Last FundingOct 29, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.